We are live on ! Find out more
IDYA icon

IDEAYA Biosciences

204 hedge funds and large institutions have $2.04B invested in IDEAYA Biosciences in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 78 increasing their positions, 74 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

32% more capital invested

Capital invested by funds: $1.54B → $2.04B (+$493M)

3.3% more ownership

Funds ownership: 107.24%110.54% (+3.3%)

5% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 74

0% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 31

1% less funds holding

Funds holding: 207204 (-3)

68% less call options, than puts

Call options by funds: $887K | Put options by funds: $2.77M

Holders
204
Holders Change
-3
Holders Change %
-1.45%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.05%
New
31
Increased
78
Reduced
74
Closed
31
Calls
$887K
Puts
$2.77M
Net Calls
-$1.89M
Net Calls Change
-$2.73M
Name Holding Trade Value Shares
Change
Change in
Stake
Ensign Peak Advisors
26
Ensign Peak Advisors
Utah
$15.6M +$7.95M +414,189 +126%
Charles Schwab
27
Charles Schwab
California
$15.1M +$251K +13,082 +2%
Northern Trust
28
Northern Trust
Illinois
$15M -$732K -38,173 -5%
DCM
29
DAFNA Capital Management
California
$13M +$571K +29,760 +5%
Qube Research & Technologies (QRT)
30
Qube Research & Technologies (QRT)
United Kingdom
$11.1M -$8.89M -463,457 -47%
RA
31
Rosalind Advisors
Ontario, Canada
$10.7M -$3.62M -188,868 -27%
JP Morgan Chase
32
JP Morgan Chase
New York
$9.38M +$2.22M +115,827 +35%
Aberdeen Group
33
Aberdeen Group
United Kingdom
$9.28M
RG
34
Redmile Group
California
$9.09M -$1.96M -102,106 -19%
Deutsche Bank
35
Deutsche Bank
Germany
$8.73M -$999K -52,062 -11%
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$8.44M +$1.35M +70,620 +21%
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$7.94M +$4.9M +255,312 +208%
Axa
38
Axa
France
$6.82M +$10K +523 +0.2%
Barclays
39
Barclays
United Kingdom
$6.75M +$2.61M +135,800 +73%
Voloridge Investment Management
40
Voloridge Investment Management
Florida
$5.97M -$187K -9,764 -3%
UBS AM
41
UBS AM
Illinois
$5.73M -$585K -30,485 -10%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$5.6M -$2.82M -147,000 -36%
GAI
43
General American Investors
New York
$5.47M
AG
44
Algert Global
California
$5.32M -$1.03M -53,628 -17%
SCM
45
Soleus Capital Management
Connecticut
$5.25M +$4.8M +250,000 New
Bank of New York Mellon
46
Bank of New York Mellon
New York
$5.25M +$444K +23,155 +10%
WCM Investment Management
47
WCM Investment Management
California
$5.12M -$83.3K -4,343 -2%
WP
48
Woodline Partners
California
$4.76M -$1.71M -88,982 -28%
Schroder Investment Management Group
49
Schroder Investment Management Group
United Kingdom
$4.64M -$799K -41,654 -16%
N
50
Nuveen
North Carolina
$4.57M -$1.34M -69,994 -24%

IDYA Hedge Fund Activity: Q2 2025 in Review

204 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in IDEAYA Biosciences (IDYA) for Q2 2025, worth a combined $2.04B — up 32% from $1.54B a quarter earlier.

Fund positioning in IDYA was balanced in Q2 2025: 31 funds opened new positions, 31 closed out, 78 added to existing stakes and 74 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $93.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $30.1M.

  • 204 institutional investors held IDEAYA Biosciences (IDYA) as of Q2 2025, down from 207 in Q1 2025.
  • Funds reported $2.04B of IDEAYA Biosciences stock for Q2 2025, up 32% quarter-over-quarter.
  • 31 funds opened new IDEAYA Biosciences positions in Q2 2025 and 31 closed out, a net change of 0 holders.
  • The largest IDEAYA Biosciences buyer in Q2 2025 was Point72 Asset Management, an estimated $93.8M added.
  • The largest IDEAYA Biosciences seller in Q2 2025 was T. Rowe Price Associates, an estimated $30.1M sold.

Based on aggregated 13F filings for Q2 2025.